Abstract 185P
Background
LIF is an interleukin 6 class cytokine that plays a crucial role in the development of many solid tumors. Herein, we identify the elusive role of LIF in clear cell renal cell carcinoma (ccRCC) and its impact on tumor immune microenvironment.
Methods
The human cancer genome atlas (TCGA) was utilized to obtain ccRCC clinicopathological and expression data. The prognostic utility of LIF expression in ccRCC was evaluated using univariate and multivariate Cox logistic regression analysis. Co-expressed genes were explored using LinkedOmics and their biological roles were identified using gene set enrichment analysis (GSEA) through KEGG pathways terminology. The immune microenvironment was evaluated using Tumor IMmune Estimation Resource (TIMER 2.0). Correlations between LIF expression and immune-related genes were obtained using the Gene Expression Profiling Interactive Analysis (GEPIA).
Results
High LIF expression is associated with shortened overall survival (HR: 1.828, 95% CI: 1.358-2.460, P < .0001) in TCGA ccRCC cohort. Multivariate Cox logistic regression analysis identified LIF expression as an independent prognostic variable (HR: 0.48, 95% CI: 0.303-0.759, P = .002). GSEA showed enrichment in IL-17, TNF, JAK-STAT and NF-kB signaling pathways besides cytokine-cytokine receptor interaction, transcriptional misregulation in cancer, complement and coagulation cascades. LIF expression is positively corelated with immunosuppressive cellular elements including Tregs (ρ = 0.14, Q = 0.012), M2 macrophages (ρ = 0.25, Q < .0001), and myeloidderived suppressor cells (ρ = 0.18, Q value < .001). In addition, LIF corelated significantly with Tregs-related genes including FOXP3 (ρ = 0.28, P < .0001), CCR8 (ρ = 0.23, P < .0001), and TGF-β (ρ = 0.38, P < .0001). M2 macrophages-related genes were also significantly corelated with LIF expression as in CD163 (ρ = 0.30, P < .0001), VSIG4 (ρ = 0.27, P < .0001), and MS4A4A (ρ = 0.24, P < .0001). Immune check points genes were also influenced by LIF expression including CTLA4 (ρ = 0.25, P < .0001) and LAG3 (ρ = 0.21, P < .0001).
Conclusions
LIF upregulation corelates with poor prognosis in ccRCC and induces an immune suppressed microenvironment.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
100P - Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: updated efficacy and safety results
Presenter: Jianqing Zhu
Session: Poster Display
101P - Progression-Free Survival is an acceptable surrogate endpoint for chemo-immunotherapy combinations in Cervical Carcinoma, an EORTC Young GCG study
Presenter: Ramon Yarza
Session: Poster Display
102P - Interim safety analysis of a phase 2 trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer
Presenter: Oladapo Yeku
Session: Poster Display
103P - Long-term survivorship rates among previously treated patients with advanced renal cell carcinoma (aRCC) achieving objective response with nivolumab
Presenter: Saby George
Session: Poster Display
105P - Preliminary efficacy and safety results from ‘ReBirth’, a phase II study of risk-based bladder-sparing therapy for MIBC.
Presenter: Yijun Shen
Session: Poster Display
106P - Treatment Sequencing in PD-L1-Positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Exploratory Analysis of the Phase 3 KEYNOTE-048 Study
Presenter: Amanda Psyrri
Session: Poster Display
108P - Real-world (RW) effectiveness and safety of adjuvant nivolumab (NIVO) in patients (pts) with melanoma in Belgium and Luxembourg: PRESERV MEL
Presenter: Bart Neyns
Session: Poster Display
109P - Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy
Presenter: Inge Noringriis
Session: Poster Display
110P - Outcomes of CUPem: A prospective Phase II multicentre clinical Trial of Pembrolizumab in patients with pre-treated Cancer of Unknown Primary
Presenter: Harpreet Wasan
Session: Poster Display